Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 9/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | MAX | P61244 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27090240 | 0.83 | BACE1 (0.40) | TSHRLMNAELANEALDH1A1MAPT | |
| SCHEMBL5691015 | 0.81 | TSHR (0.63) | CASP6TSHRTTRHCAR3MYC | |
| SCHEMBL27051801 | 0.79 | ELANE (0.49) | TSHRTTRLMNAELANEALDH1A1 | |
| SCHEMBL29753668 | 0.78 | TTR (0.64) | CASP6TSHRTTRHCAR3MYC | |
| SCHEMBL223878 | 0.78 | TTR (0.64) | CASP6TSHRTTRHCAR3MYC | |
| SCHEMBL9178134 | 0.78 | ALDH1A1 (0.36) | LMNAELANEALDH1A1 | |
| SCHEMBL557040 | 0.78 | CASP6 (0.55) | CASP6TSHRHCAR3LMNAMAPT | |
| SCHEMBL557039 | 0.78 | CASP6 (0.55) | CASP6TSHRHCAR3LMNAMAPT | |
| SCHEMBL7339887 | 0.76 | TSHR (0.73) | CASP6TSHRHCAR3LMNAALDH1A1 | |
| SCHEMBL26343189 | 0.76 | DTYMK (0.48) | CASP6TSHRTTRELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589097-B2 | Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1392312-B1 | TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-09-25 | — | — | US | disclosed |
| US-7405219-B2 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2007-03-01 | — | — | US | disclosed |
| US-7141575-B2 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LTD. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | disclosed |
| EP-1392312-A1 | TRIAZOLO 4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002055083-A1 | TRIAZOLO[4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234296-A1 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | CASP6 1392/4885TSHR 219/4885TTR 3553/4885 |
| US-20070049607-A1 | Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, ADORA2A, CHRNA4 | CASP6 1681/4885TSHR 185/4885TTR 3579/4885 |
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | CASP6 1822/4885TSHR 244/4885TTR 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.